Immunization with Killed Influenza Virus in Children with Chronic Asthma

Bell, Thomas D.; Chai, Hyman; Berlow, Bruce; Daniels, Gregory A.

doi:10.1378/chest.73.2.140

Cited by 74 publications

(31 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found, however, the vaccine to be more effective in children older than 7 years of age, but effect modification by age was not statistically confirmed. In 1974 Bell et al observed a 66 % reduction in hospitalization days due to influenza-like-illness and to influenza-like-illness and asthma, but not due to asthma alone [34]. Although both studies, like ours, included asthmatic children, there are some major differences.…”

Section: Discussionmentioning

confidence: 63%

Clinical effectiveness of conventional influenza vaccination in asthmatic children

et al. 2002

View full text Add to dashboard Cite

SUMMARYInfluenza immunization rates among young asthmatics remain unsatisfactory due to persistent concern about the impact of influenza and the benefits of the vaccine. We assessed the effectiveness of the conventional inactivated trivalent sub-unit influenza vaccine in reducing acute respiratory disease in asthmatic children. We conducted a two-season retrospective cohort study covering the 1995-6 and 1996-7 influenza outbreaks in 22 computerized primary care practices in the Netherlands. In total, 349 patients aged between 0 and 12 years meeting clinical asthma-criteria were included ; 14 children were lost to follow-up in the second season. The occurrence of physician-diagnosed acute respiratory disease episodes including influenzalike illness, pneumonia, bronchitis, bronchiolitis, asthma exacerbation and acute otitis media in vaccinated and unvaccinated children were compared after adjustments for age, prior health care and medication use. The occurrence of acute respiratory disease in unvaccinated children was 28 % and 24 % in the 1995-6 and 1996-7 season, respectively, and was highest in children under 6 years of age (43 %). The overall pooled clinical vaccine effectiveness was 27 % (95 % confidence interval k7 to 51%, P l 0n11) after adjustments. A statistically higher vaccine protectiveness of 55 % (95 % CI 20-75 %, P l 0n01) was observed among asthmatics under 6 years of age compared with k5 % in older children (95 % CI k81 to 39 %).

show abstract

Section: Discussionmentioning

confidence: 63%

Clinical effectiveness of conventional influenza vaccination in asthmatic children

et al. 2002

View full text Add to dashboard Cite

show abstract

“…[37][38][39] Nevertheless, infl u enza vaccine effectiveness has been demonstrated among children and adults with other chronic respiratory diseases. [40][41][42][43] Additionally, a small, retrospective This study demonstrated for the fi rst time to our knowledge that CF pulmonary exacerbations increase signifi cantly during the winter and that they are highly associated with the infl uenza season.…”

Section: Sensitivity Analysesmentioning

confidence: 99%

Influenza-Associated Cystic Fibrosis Pulmonary Exacerbations

Ortiz

Neuzil

Victor

et al. 2010

Chest

View full text Add to dashboard Cite

A n estimated 30,000 people in the United States have cystic fi brosis (CF). 1 CF is an autosomal reces sive disease that affects multiple organ systems; however, respiratory complications account for nearly 85% of CF mortality. 1 Exacerbations of CF pulmonary disease are common and are characterized by cough, increased sputum production, dyspnea, decreased energy level and appetite, weight loss, and decreases in spirometric parameters. 2 Over the last 2 decades, the quality of life and median survival among persons with CF have improved substantially. 1 Nevertheless, increasing age in CF is associated with worsening nutritional status, declining lung function,

show abstract

“…11 Results of studies evaluating the effect of TIV administration on symptoms and pulmonary function in children with asthma have been mixed. [12][13][14][15][16][17][18] Live attenuated influenza vaccine (LAIV, FluMist; MedImmune, Gaithersburg, MD) is a cold-adapted, temperature-sensitive, trivalent influenza vaccine currently approved for prevention of influenza in healthy children between 5 and 19 years of age. 19 -21 To date, the safety of LAIV has been studied in only a small number of children with asthma.…”

mentioning

confidence: 99%